GLP-1 drugs are almost single-handedly forcing employers to reconsider how they pay for their workers’ care.

In today's Pharmalittle newsletter, drug pricing deals, a new cancer therapy approval, and more of the latest pharma ...

Caution and survival in radiopharmaceuticals, mRNA skepticism, and more biotech news from The Readout ...

The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an ...

A drug patent case involving Amgen is being closely watched given its potential implications for pharmaceutical patent deals ...

With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the ...

The mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from ...

STAT examines Republicans’ health care funding cuts, mRNA science defeats politics, and Medicaid tries out a new way to deny ...

An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.

Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-verification ...

A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's heart health.

A scramble to prepare for massive federal cuts across the health care system is hitting rural states like Maine particularly ...